2.53
price up icon4.12%   0.10
after-market 시간 외 거래: 2.58 0.05 +1.98%
loading
전일 마감가:
$2.43
열려 있는:
$2.42
하루 거래량:
133.00K
Relative Volume:
0.33
시가총액:
$67.89M
수익:
$9.94M
순이익/손실:
$-144.49M
주가수익비율:
-0.4521
EPS:
-5.5956
순현금흐름:
$-103.90M
1주 성능:
+0.00%
1개월 성능:
+29.08%
6개월 성능:
-50.68%
1년 성능:
+2.02%
1일 변동 폭
Value
$2.42
$2.59
1주일 범위
Value
$2.06
$2.6198
52주 변동 폭
Value
$1.43
$8.17

Syros Pharmaceuticals Inc Stock (SYRS) Company Profile

Name
명칭
Syros Pharmaceuticals Inc
Name
전화
617-744-1340
Name
주소
35 CAMBRIDGE PARK DRIVE, CAMBRIDGE
Name
직원
68
Name
트위터
@syrospharma
Name
다음 수익 날짜
2024-10-31
Name
최신 SEC 제출 서류
Name
SYRS's Discussions on Twitter

Syros Pharmaceuticals Inc Stock (SYRS) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2020-11-04 업그레이드 H.C. Wainwright Neutral → Buy
2020-09-22 개시 Alliance Global Partners Buy
2020-01-17 다운그레이드 Wedbush Outperform → Neutral
2019-03-08 재개 JMP Securities Mkt Outperform
2019-02-14 재개 Oppenheimer Outperform
2018-11-05 업그레이드 ROTH Capital Neutral → Buy
2018-03-13 재확인 Wedbush Outperform
2017-10-31 재개 Piper Jaffray Overweight
2017-10-23 개시 ROTH Capital Neutral
2017-08-10 다운그레이드 JMP Securities Mkt Outperform → Mkt Perform
모두보기

Syros Pharmaceuticals Inc 주식(SYRS)의 최신 뉴스

pulisher
Nov 04, 2024

Syros Pharmaceuticals (NASDAQ:SYRS) Rating Lowered to Sell at StockNews.com - MarketBeat

Nov 04, 2024
pulisher
Nov 04, 2024

SYRS (Syros Pharmaceuticals) Total Inventories : $0.00 Mil (As of Sep. 2024) - GuruFocus.com

Nov 04, 2024
pulisher
Nov 04, 2024

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2024 Earnings Call Transcript - MSN

Nov 04, 2024
pulisher
Nov 04, 2024

Syros Pharmaceuticals, Inc. announced that it expects to receive $10 million in funding from Incyte Corporation - Marketscreener.com

Nov 04, 2024
pulisher
Nov 03, 2024

Incyte Corporation and yros Pharmaceuticals Announce Global Target Discovery and Validation Collaboration Focused on Myeloproliferative Neoplasms - Marketscreener.com

Nov 03, 2024
pulisher
Nov 02, 2024

SYRSW (Syros Pharmaceuticals) 5-Year Dividend Growth Rate : 0.00% (As of Jun. 2024) - GuruFocus.com

Nov 02, 2024
pulisher
Nov 02, 2024

Syros Pharmaceuticals Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023) - Yahoo Finance

Nov 02, 2024
pulisher
Nov 01, 2024

Syros Pharmaceuticals (NASDAQ:SYRS) Issues Quarterly Earnings Results - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Earnings call: Syros Pharmaceuticals outlines tamibarotene progress - Investing.com

Nov 01, 2024
pulisher
Nov 01, 2024

Syros Pharmaceuticals Inc (SYRS) Q3 2024 Earnings Call Highlights: Strategic Focus on ... - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Syros Pharmaceuticals (NASDAQ:SYRS) Earns Buy Rating from HC Wainwright - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Syros Pharmaceuticals Inc (SYRS) Q3 2024 Earnings Call Highlight - GuruFocus.com

Nov 01, 2024
pulisher
Nov 01, 2024

Syros Pharmaceuticals Reports Q3 2024 Financial Results - TipRanks

Nov 01, 2024
pulisher
Oct 31, 2024

Q3 2024 Syros Pharmaceuticals Inc Earnings Call Transcript - GuruFocus.com

Oct 31, 2024
pulisher
Oct 31, 2024

Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update - StockTitan

Oct 31, 2024
pulisher
Oct 31, 2024

Syros Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Oct 31, 2024
pulisher
Oct 25, 2024

Syros Pharmaceuticals (SYRS) Loses -70.55% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN

Oct 25, 2024
pulisher
Oct 25, 2024

Syros Pharmaceuticals (SYRS) Set to Announce Earnings on Thursday - MarketBeat

Oct 25, 2024
pulisher
Oct 25, 2024

Syros Pharmaceuticals' SWOT analysis: stock outlook amid clinical setbacks - Investing.com India

Oct 25, 2024
pulisher
Oct 24, 2024

Syros Pharmaceuticals' SWOT analysis: stock outlook amid clinical setbacks By Investing.com - Investing.com Australia

Oct 24, 2024
pulisher
Oct 23, 2024

Piper Sandler reaffirms overweight rating and $5 PT on Syros Pharmaceuticals stock - Investing.com UK

Oct 23, 2024
pulisher
Oct 15, 2024

Syros Pharmaceuticals (NASDAQ:SYRS) Upgraded by StockNews.com to "Hold" - MarketBeat

Oct 15, 2024
pulisher
Oct 09, 2024

Syros Pharmaceuticals Inc (SYRS) Q2 2024 Earnings Call Highlights: Strategic Focus on ... - Yahoo Finance

Oct 09, 2024
pulisher
Oct 07, 2024

Syros Pharmaceuticals (NASDAQ:SYRS) Downgraded by StockNews.com - MarketBeat

Oct 07, 2024
pulisher
Oct 02, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc.SYRS - cnhinews.com

Oct 02, 2024
pulisher
Sep 30, 2024

Syros Pharmaceuticals' SWOT analysis: stock faces challenges amid clinical setbacks By Investing.com - Investing.com South Africa

Sep 30, 2024
pulisher
Sep 30, 2024

Syros Pharmaceuticals' SWOT analysis: stock faces challenges amid clinical setbacks - Investing.com India

Sep 30, 2024
pulisher
Sep 24, 2024

575,000 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Bought by Logos Global Management LP - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Ratios Uncovered: Breaking Down Spyre Therapeutics Inc. (SYRE)’s Trailing Twelve Months Metrics - The Dwinnex

Sep 24, 2024
pulisher
Sep 24, 2024

Symphony Environmental Technologies (LON:SYM) Shares Down 13.8% - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Spyre Therapeutics Inc.’s results are impressive - US Post News

Sep 24, 2024
pulisher
Sep 24, 2024

Farallon Capital Management LLC Buys Shares of 666,000 Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat

Sep 24, 2024
pulisher
Sep 23, 2024

100,000 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Purchased by Integral Health Asset Management LLC - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Down to $30.17 - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

Xilio Therapeutics Inc (XLO) rating initates by Chardan Capital Markets - Knox Daily

Sep 23, 2024
pulisher
Sep 23, 2024

Itau Unibanco Holding S.A. Takes $435,000 Position in Ross Stores, Inc. (NASDAQ:ROST) - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Avoro Capital Advisors LLC Purchases Shares of 1,839,138 Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Canada Pension Plan Investment Board Acquires 509,700 Shares of Symbotic Inc. (NASDAQ:SYM) - Defense World

Sep 23, 2024
pulisher
Sep 21, 2024

Symbotic (NASDAQ:SYM) Shares Up 2.1% - Defense World

Sep 21, 2024
pulisher
Sep 20, 2024

Arm Joins the PHLX Semiconductor Sector Index℠ (SOX℠) - sharewise

Sep 20, 2024
pulisher
Sep 19, 2024

The Principles of Low-Carbon Tectonics: As Lygos, Pyran accelerate, we look at the why, the where, and the when - Biofuels Digest

Sep 19, 2024
pulisher
Sep 19, 2024

Symbotic (NASDAQ:SYM) Shares Gap Up to $22.41 - Defense World

Sep 19, 2024
pulisher
Sep 18, 2024

Quarterly Metrics: Quick and Current Ratios for Symbotic Inc (SYM) - The Dwinnex

Sep 18, 2024
pulisher
Sep 18, 2024

Wall Street analysts’ outlook for Symbotic Inc (SYM) - SETE News

Sep 18, 2024
pulisher
Sep 17, 2024

Understanding the Risks of Investing in Syros Pharmaceuticals Inc. (SYRS) - Knox Daily

Sep 17, 2024
pulisher
Sep 17, 2024

Siyata Mobile Inc (SYTA) expanding its growth trajectory ahead - SETE News

Sep 17, 2024
pulisher
Sep 17, 2024

What is the investor’s view on Syros Pharmaceuticals Inc. (SYRS)? - US Post News

Sep 17, 2024
pulisher
Sep 14, 2024

Syros Pharmaceuticals Chief Financial Officer Acquires 407% More Stock - Simply Wall St

Sep 14, 2024
pulisher
Sep 13, 2024

Syros Pharmaceuticals Inc. [SYRS] Shares Fall Approximately -60.45% Over the Year - Knox Daily

Sep 13, 2024
pulisher
Sep 13, 2024

Syros Pharmaceuticals Inc.’s Shares Reel: -70.93% Quarterly Revenue Decline Amid 41.97M Market Cap - The InvestChronicle

Sep 13, 2024
pulisher
Sep 13, 2024

Syros pharmaceuticals CEO buys shares worth over $160k By Investing.com - Investing.com Australia

Sep 13, 2024

Syros Pharmaceuticals Inc (SYRS) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Syros Pharmaceuticals Inc 주식 (SYRS) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Haas Jason
Chief Financial Officer
Sep 12 '24
Buy
1.68
45,344
76,006
124,552
Chee Conley
President & CEO
Sep 10 '24
Buy
1.51
50,000
75,260
72,504
Haas Jason
Chief Financial Officer
Sep 10 '24
Buy
1.55
35,363
54,788
59,915
Haas Jason
Chief Financial Officer
Sep 11 '24
Buy
1.58
19,293
30,446
79,208
Young Richard A
Director
Jun 28 '24
Sale
5.12
34,837
178,365
8,000
Roth David
Chief Medical Officer
Apr 03 '24
Sale
4.95
10,451
51,732
0
Roth David
Chief Medical Officer
Apr 02 '24
Sale
4.98
150
747
10,451
AKKARAJU SRINIVAS
Director
Dec 21 '23
Buy
4.42
904,977
3,999,998
1,786,427
Roth David
Chief Medical Officer
Dec 12 '23
Sale
4.95
6,287
31,121
0
Roth David
Chief Medical Officer
Dec 06 '23
Sale
3.95
6,287
24,834
6,287
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
자본화:     |  볼륨(24시간):